CSIMarket Company Name, Ticker, Industry, else..
 
Mdxhealth Sa  (NASDAQ: MDXH)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $0.7140 $-0.01 -0.833%
Day's High: $0.7490000128746033 Week Perf: -1.11 %
Day's Low: $ 0.71 30 Day Perf: 61.54 %
Volume (M): 60,340 52 Wk High: $ 5.33
Volume (M$): $ 0 52 Wk Avg: $2.57
Open: $0.72 52 Wk Low: $0.40



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 202
 Revenues (TTM) (Millions $) 108
 Net Income (TTM) (Millions $) -34
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 1

Business Description


MDxHealth SA is a molecular diagnostics company that specializes in the development and commercialization of advanced tests for urologic cancers. The company offers a range of products and services, including urine-based molecular tests for the diagnosis and management of prostate cancer. These tests are designed to provide valuable information to help healthcare professionals make informed decisions about patient treatment options. MDxHealth SA is committed to advancing precision medicine and improving patient outcomes in the field of urology.


   Company Address: Zone Industrielle des Hauts-Sarts Herstal 4040
   Company Phone Number: 812-6979   Stock Exchange / Ticker: NASDAQ MDXH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
DGX   -1.52%    
EXAS        0.29% 
GH   -3.57%    
LH   -0.15%    
NTRA   -4.08%    
VCYT        0.04% 
• View Complete Report
   



Announcement

MDxHealth to Participate in Piper Sandler Healthcare Conference

Published Mon, Nov 25 2024 1:30 PM UTC

MDxHealth: A Struggling Stock Amidst Industry ChallengesMDxHealth, a company specializing in molecular diagnostics for urological diseases, recently announced its participation in the Piper Sandler Healthcare Conference, an event that often showcases promising companies in the healthcare sector. However, in stark contrast to the optimism associated with conference participa...
Announcement

MDxHealths Financial Resurgence Navigating Challenges in a Competitive Medical Landscape

Published Thu, Sep 26 2024 1:32 AM UTC

In a bold move signaling both resilience and ambition, MDxHealth SA has announced the pricing of its offering of ordinary shares, charting a course through a tumultuous financial landscape. As the healthcare market continues to evolve, MDxHealth is making critical choices that may pave the way for future growth despite a challenging period marked by significant losses.For th...
Announcement

MDxHealths Strategic Share Offering Paving the Path for Growth and Innovation,

Published Wed, Sep 25 2024 8:05 PM UTC

By MDxHealth, a leader in molecular diagnostics and personalized medicine, recently announced the launch of an offering of ordinary shares. This strategic move is poised to reshape the company s financial structure and support its ambitious growth plans. By delving into the details and implications of this new offering, we can better understand its significance for stakehol...
Financing Agreement

MDxHealth Achieves Record-Breaking Leverage Ratio and Secures Growth Capital, Cementing Its Position as a Leader in Precision Diagnostics

Published Wed, May 1 2024 11:45 AM UTC

MDxHealth Reports Record-High Leverage Ratio for Q4 2022, Signals a Promising Future for the Company
MDxHealth, a leading precision diagnostics company, announced its Q1-2024 results and a significant boost in its Leverage Ratio, coupled with an infusion of growth capital from OrbiMed. Despite a net increase in borrowings, MDxHealth Sa managed to achieve a remarkable Lev...
Announcement

MDxHealth's Game-Changing Genetic Test Strengthens Prostate Cancer Detection and Treatment

Published Tue, Mar 12 2024 8:00 PM UTC

MDxHealth Expands Prostate Cancer Testing Capabilities with Addition of Hereditary Prostate Cancer Genetic TestIn a recent press release, MDxHealth announced the inclusion of a new hereditary prostate cancer genetic test to their existing portfolio of prostate cancer offerings. This development marks a significant step in the field of prostate cancer diagnostics, as it enabl...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.34
Working Capital Ratio 0.58
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 534,035
Net Income per Employee (TTM) -165,936
Receivable Turnover Ratio (TTM) 29.4
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.78

Profitability Ratios Current
Gross Margin (MRQ) 64.55 %
Operating Margin (MRQ) -13.36 %
Net Margin (MRQ) -31.07 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Mdxhealth Sa's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.